Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Rosti

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Expert Opinion on Biological Therapy|September 6, 2012
Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patientsMassimo Martino, Alberto Bottini, Giovanni Rosti, et al.
Expert Review of Hematology|June 29, 2017
Position paper on management of iron deficiency in adult cancer patientsSandro Barni, Pere Gascòn, Fausto Petrelli, et al.
Critical Reviews in Oncology/Hematology|February 22, 2002
High-dose chemotherapy for solid tumors: results of the EBMTGiovanni Rosti, Patrizia Ferrante, Jonathan Ledermann, et al.
Cancer|July 19, 2002
Salvage high-dose chemotherapy in patients with germ cell tumors: an Italian experience with 84 patientsGiovanni Rosti, Ugo De Giorgi, Roberto Salvioni, et al.
Therapeutic Advances in Medical Oncology|June 4, 2026
Treatment options in platinum-refractory male germ cell cancers: current standards and future directionsMarco Oltrecolli, Domiziana Alaimo, Fabrizio Di Costanzo, et al.
The International Journal of Biological Markers|May 19, 2015
Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 functionUgo De Giorgi, Juping Yuan, Mauro Moroni, et al.
International Journal of Radiation Oncology, Biology, Physics|May 10, 2006
Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancerUgo De Giorgi, Massimo Giannini, Luca Frassineti, et al.
European Urology|June 8, 2006
Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumorUgo De Giorgi, Giovanni Rosti, Michele Aieta, et al.
Haematologica|October 8, 2008
Consensus conference on the management of tumor lysis syndromePatrizia Tosi, Giovanni Barosi, Carlo Lazzaro, et al.
Journal of the National Cancer Institute|April 10, 2008
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trialSerge Leyvraz, Sandro Pampallona, Giovanni Martinelli, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Expert Opinion on Biological Therapy|September 6, 2012
Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patientsMassimo Martino, Alberto Bottini, Giovanni Rosti, et al.
Expert Review of Hematology|June 29, 2017
Position paper on management of iron deficiency in adult cancer patientsSandro Barni, Pere Gascòn, Fausto Petrelli, et al.
Critical Reviews in Oncology/Hematology|February 22, 2002
High-dose chemotherapy for solid tumors: results of the EBMTGiovanni Rosti, Patrizia Ferrante, Jonathan Ledermann, et al.
Cancer|July 19, 2002
Salvage high-dose chemotherapy in patients with germ cell tumors: an Italian experience with 84 patientsGiovanni Rosti, Ugo De Giorgi, Roberto Salvioni, et al.
Therapeutic Advances in Medical Oncology|June 4, 2026
Treatment options in platinum-refractory male germ cell cancers: current standards and future directionsMarco Oltrecolli, Domiziana Alaimo, Fabrizio Di Costanzo, et al.
The International Journal of Biological Markers|May 19, 2015
Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 functionUgo De Giorgi, Juping Yuan, Mauro Moroni, et al.
International Journal of Radiation Oncology, Biology, Physics|May 10, 2006
Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancerUgo De Giorgi, Massimo Giannini, Luca Frassineti, et al.
European Urology|June 8, 2006
Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumorUgo De Giorgi, Giovanni Rosti, Michele Aieta, et al.
Haematologica|October 8, 2008
Consensus conference on the management of tumor lysis syndromePatrizia Tosi, Giovanni Barosi, Carlo Lazzaro, et al.
Journal of the National Cancer Institute|April 10, 2008
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trialSerge Leyvraz, Sandro Pampallona, Giovanni Martinelli, et al.
Pageof 9